Australia Prepares Swift Reforms to PBS Listing as Trump Threatens 250% Drug Tariffs
AUSTRALIA, AUG 6 – Industry leaders warn excessive wait times for new medicines on Australia's Pharmaceutical Benefits Scheme could delay treatments by up to 22 months, posing a greater risk than US tariffs.
- The Australian government is advancing reforms to speed up listing medicines on the Pharmaceutical Benefits Scheme amid US tariff threats.
- The reforms follow a Health Technology Assessment review delivered last year that recommended streamlining the PBS process to improve access.
- US President Donald Trump has imposed tariffs on pharmaceuticals, threatening to raise them to 250 per cent unless drugs are made in America.
- Mr Trump told CNBC, "it's going to go to 150 per cent and then it's going to go to 250 per cent" reflecting his push for domestic production.
- Australia aims to improve drug approval speed and protect the PBS, which remains off limits to trade negotiations despite US industry pressure.
Insights by Ground AI
Does this summary seem wrong?
9 Articles
9 Articles

+3 Reposted by 3 other sources
‘A very big threat’: Australia defends PBS as Trump flags 250% tariffs on medicines
As Trump made his latest threat, Health Minister Mark Butler said it would not change how Australians accessed their medicines through the Pharmaceutical Benefits Scheme. But he stressed the government was concerned about how tariffs would hit $2 billion worth of medicines sold to the US by Australian importers.
·Sydney, Australia
Read Full Article

New wave of Trump tariffs hit amid fears over medicines
US President Donald Trump’s latest wave of tariffs have come into effect, hitting dozens of countries. It comes as Australia raised the alarm over tariffs jeopardising access to affordable medicines.
·Australia
Read Full ArticleCoverage Details
Total News Sources9
Leaning Left3Leaning Right3Center1Last UpdatedBias Distribution43% Left, 43% Right
Bias Distribution
- 43% of the sources lean Left, 43% of the sources lean Right
43% Right
L 43%
14%
R 43%
Factuality
To view factuality data please Upgrade to Premium